Blog from IFPMA ADG Greg Perry following his visit to Cabo Verde
Find out here an insight that Greg Perry gives around WHO Afro Global Health Forum 2019
Read More
Thought Leader Series in Vaccines
A mustread from experts talking about the value of vaccines
Read More
Our response to Zika virus
Check here about the R&D blueprint against Zika
Read More
Women’s Cancer Initiative in the Americas
Partnership to improve prevention of women’s cancers and quality of cancer registries in LAC reaches 1 year milestone
Read More
Latest News
2020-06-08 07:54:23
Global Pharma Body Names New Communications Director
Geneva, 8 June, 2020: The industry body representing research-based biopharmaceutical companies and regional and national associations across the world has ...
Read More2020-06-04 13:02:10
Pharma pledges to continue 20 year partnership with Gavi, the Vaccine Alliance
IFPMA members have worked for 20 years with Gavi to stem the ravages of childhood ...
Read More2020-05-28 15:00:58
Pharma partners in efforts to give coronavirus vaccine for everyone
Geneva, 28 May 2020. IFPMA has today updated the world’s media on the biopharmaceutical industry’s ...
Read More2020-05-28 08:04:20
Pharma industry updates advice on engaging with healthcare professionals as countries emerge from COVID-19 lockdown
Geneva, 28 May 2020: As countries lift lockdown restrictions, the international pharma industry body, IFPMA, ...
Read More2020-05-19 15:31:26
Pharma and other innovative health groups tell World Health Assembly it stands united with governments and global health stakeholders worldwide to combat COVID-19
Geneva, May 19, 2020: At the Seventy-Third World Health Assembly, IFPMA, the industry body representing ...
Read More2020-05-04 16:28:01
Pharma Joins Global Pledge Committing to Work Together to Beat COVID-19
Geneva, 4 May, 2020: The world’s leading biopharmaceutical companies today reaffirmed the industry’s commitment to ...
Read More2020-04-30 15:25:13
Global Pharma update on unprecedented efforts to collaborate in speeding up the search for safe and effective COVID-19 therapies
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together their best people, resources and ...
Read More
Latest Statement
2020-06-26 10:12:47
IFPMA Statement - Access to COVID-19 Tools Accelerator (ACT-Accelerator) Investment Case
Geneva, 26 June 2020: Today, we face the first global pandemic in living memory; affecting hundreds of millions of people ...
Read More2020-06-04 13:01:49
Biopharmaceutical Industry Statement at Gavi, the Vaccine Alliance – Global Vaccine Summit 2020
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together ...
Read More2020-05-28 19:14:41
IFPMA Statement on the “Solidarity Call to Action to realize equitable global access to COVID-19 health technologies through pooling of knowledge, intellectual property and data”
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together ...
Read More2020-05-18 08:01:23
Joint Statement – Innovative Health Industries @ WHA73
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together ...
Read More2020-05-04 16:23:13
Pharma Statement for The Coronavirus Global Response Pledging Marathon
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together ...
Read More2020-04-24 13:41:50
IFPMA Statement on the launch of a new global collaboration to accelerate the development, production and equitable access to new COVID-19 tools
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together ...
Read More2020-04-21 09:01:40
Innovative health industries united in welcoming United Nations General Assembly Resolution on “International Cooperation to ensure global access to medicines, vaccines and medical equipment to face COVID-19"
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together ...
Read More
mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig
Sadia Kaenzig - Communications Manager
Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.
mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol
Morgane De Pol - Communications and Public Affairs
Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.
Our Brouchure
2015 Edition
A shared commitment to global health
At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.
Our Logo
Full colour EPS format
Our Logo
Full colour PNG format
FULL Name LOGO
Full colour EPS format
FULL Name LOGO
Full colour PNG format
Hot Topic
Pharmacovigilance: Do your bit, play your part!
Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is
Read MoreInterview
IFPMA 2015 interview series 'Biodiversity, human health, and pharma'
A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to
Read MoreOur Blog
Reinforcing Business Integrity for APEC Health Systems Amidst COVID-19
Authors: Dr. Jeff Blackmer, Mr. Thomas Cueni, Mr. Gaston Fernandez, Ms. Nancy Travis, Mr. Russell Williams The dual health and economic crisis resulting from COVID-19 has brought into sharp focus the importance of ethical business conduct. Emergency government measures, widespread economic and social disruption, as well as unscrupulous actors taking advantage of the current situation for personal gain are testing business integrity for SMEs and...
Read More
What will it take to produce the billions of vaccines needed against COVID-19?
Published on Thomas Cueni's LinkedIn profile. COVID-19 is not business as usual for any of us, especially not for the pharmaceutical industry. As we enter into the sixth month of the COVID-19 pandemic, I think it is no understatement to say that the global biopharmaceutical industry has been at the forefront of efforts from day one. In the past months, rarely a day has gone...
Read More
Interview - BBC Sounds - Coronavirus: Are we on the road to recovery?
Thomas Cueni, IFPMA Director General, spoke to BBC Sounds on 26 May on about the extent and importance of collaborations both between biopharmaceutical companies and with other stakeholders, notably universities and biotech companies to combat the COVID-19 crisis. At this stage, it is still impossible to know with certainty whether there will be a vaccine, but he is confident a vaccine will be developed, even...
Read MoreLatest Tweets
